肾细胞癌术后肿瘤学结局预测模型
该研究基于Mayo Clinic 1980至2010年肾切除登记库,回顾性纳入3633例非转移性肾细胞癌患者,按透明细胞、乳头状和嫌色细胞亚型分别构建预测无进展生存和癌症特异性生存的预后模型,各模型c-index在0.77至0.86之间,但嫌色细胞癌因死亡事件少未行多变量分析,且缺乏外部验证。
要点
- 按ccRCC、papRCC、chrRCC亚型分别建立PFS和CSS预后模型及风险分组。
- PFS模型c-index:ccRCC 0.83、papRCC 0.77、chrRCC 0.78。
- CSS模型c-index:ccRCC 0.86、papRCC 0.83;chrRCC因仅22例死亡未建多变量模型。
核心结论
- 基于大型单中心经验,为ccRCC、papRCC和chrRCC建立了依赖既往已验证生存相关特征的特定预后模型,可辅助患者预后判断、生物标志物设计和临床试验入组。
研究设计与样本
- 回顾性队列研究,纳入Mayo Clinic肾切除登记库1980至2010年接受部分或根治性肾切除术的非转移性ccRCC、papRCC和chrRCC患者,共3633例。
- 其中ccRCC 2726例(75%)、papRCC 607例(17%)、chrRCC 222例(6%)。
- 采用多变量Cox比例风险回归构建简约模型,以c-index评价,并转换为风险评分/分组预测PFS和CSS。
主要发现
- 为每种组织学亚型分别生成模型,并为每个亚型和结局(PFS/CSS)开发风险评分/分组。
- PFS的c-index分别为ccRCC 0.83、papRCC 0.77、chrRCC 0.78。
- CSS的c-index分别为ccRCC 0.86、papRCC 0.83。
- chrRCC因仅22例RCC死亡,未评估多变量模型。
关键数值与推荐
- PFS模型c-index:ccRCC 0.83、papRCC 0.77、chrRCC 0.78。
- CSS模型c-index:ccRCC 0.86、papRCC 0.83。
- chrRCC的CSS多变量模型未评估,因仅22例RCC死亡。
临床怎么用
- 可利用常规临床和病理特征预测肾细胞癌术后进展和死亡风险,辅助患者咨询。
- 模型可用于生物标志物研究设计和临床试验入组分层。
局限性
- 单中心研究。
- 缺乏外部验证。
- 回顾性研究性质。
- chrRCC因RCC死亡事件少(22例)未建立多变量CSS模型。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Predicting oncologic outcomes is important for patient counseling, clinical trial design, and biomarker study testing. OBJECTIVE: To develop prognostic models for progression-free (PFS) and cancer-specific survival (CSS) in patients with clear cell renal cell carcinoma (ccRCC), papillary RCC (papRCC), and chromophobe RCC (chrRCC). DESIGN, SETTING, AND PARTICIPANTS: Retrospective cohort review of the Mayo Clinic Nephrectomy registry from 1980 to 2010, for patients with nonmetastatic ccRCC, papRCC, and chrRCC. INTERVENTION: Partial or radical nephrectomy. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: PFS and CSS from date of surgery. Multivariable Cox proportional hazards regression was used to develop parsimonious models based on clinicopathologic features to predict oncologic outcomes and were evaluated with c-indexes. Models were converted into risk scores/groupings and used to predict PFS and CSS rates after accounting for competing risks. RESULTS AND LIMITATIONS: A total of 3633 patients were identified, of whom 2726 (75%) had ccRCC, 607 (17%) had papRCC, and 222 (6%) had chrRCC. Models were generated for each histologic subtype and a risk score/grouping was developed for each subtype and outcome (PFS/CSS). For PFS, the c-indexes were 0.83, 0.77, and 0.78 for ccRCC, papRCC, and chrRCC, respectively. For CSS, c-indexes were 0.86 and 0.83 for ccRCC and papRCC. Due to only 22 deaths from RCC, we did not assess a multivariable model for chrRCC. Limitations include the single institution study, lack of external validation, and its retrospective nature. CONCLUSIONS: Using a large institutional experience, we generated specific prognostic models for oncologic outcomes in ccRCC, papRCC, and chrRCC that rely on features previously shown-and validated-to be associated with survival. These updated models should inform patient prognosis, biomarker design, and clinical trial enrollment. PATIENT SUMMARY: We identified routinely available clinical and pathologic features that can accurately predict progression and death from renal cell carcinoma following surgery. These updated models should inform patient prognosis, biomarker design, and clinical trial enrollment.
引用
- Leibovich BC, Lohse CM, Cheville JC, et al. Predicting Oncologic Outcomes in Renal Cell Carcinoma After Surgery. Eur Urol. 2018. PMID: 29398265. doi:10.1016/j.eururo.2018.01.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。